# Bio-Rad Laboratories Inc. (BIO)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $7.94B  
**Price:** $291.01 (-2.07%)

> Bio-Rad Laboratories, Inc. develops, manufactures, and markets specialized products for the clinical diagnostics and life sciences markets. In clinical diagnostics, the company provides test systems and quality control solutions for clinical laboratories. In life sciences, it produces instruments and reagents for research, biopharmaceutical production, and food testing, with a leadership position in digital PCR technology. The company operates globally across the Americas, Europe, and Asia, serving pharmaceutical companies, research institutions, clinical laboratories, and bioprocessing manufacturers. Bio-Rad also maintains a significant ownership stake in Sartorius, a supplier specializing in single-use bioprocessing technology. Founded in 1952 and headquartered in Hercules, California, the company operates a razor-and-blade business model in clinical diagnostics, combining durable instruments with recurring sales of consumable products and reagents to maintain steady revenue streams.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2.58B | $1.34B | $47M | $760M | — |
| 2024 | $2.57B | $1.38B | $269M | -$1.84B | — |
| 2023 | $2.67B | $1.43B | $338M | -$637M | — |
| 2022 | $2.80B | $1.57B | $483M | -$3.63B | — |
| 2021 | $2.92B | $1.64B | $500M | $4.25B | — |
| 2020 | $2.55B | $1.44B | $421M | $3.81B | — |
| 2019 | $2.31B | $1.26B | $230M | $1.76B | — |
| 2018 | $2.29B | $1.22B | -$103M | $366M | — |
| 2017 | $2.16B | $1.19B | $119M | $122M | — |
| 2016 | $2.07B | $1.14B | $56M | $26M | — |
| 2015 | $2.02B | $1.12B | $167M | $109M | — |
| 2014 | $2.18B | $1.18B | $150M | $89M | — |
| 2013 | $2.13B | $1.18B | $169M | $78M | — |
| 2012 | $2.07B | $1.16B | $264M | $165M | — |
| 2011 | $2.07B | $1.18B | $305M | $179M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $10.58B | $3.12B | $7.45B | $530M | $1.20B |
| 2024 | $9.36B | $2.79B | $6.57B | $488M | $1.20B |
| 2023 | $12.30B | $3.56B | $8.74B | $404M | $1.21B |
| 2022 | $13.50B | $3.89B | $9.62B | $434M | $1.20B |
| 2021 | $17.80B | $4.11B | $13.69B | $471M | $11M |
| 2020 | $12.97B | $3.09B | $9.89B | $662M | $12M |
| 2019 | $8.01B | $2.25B | $5.76B | $661M | $14M |
| 2018 | $5.61B | $1.59B | $4.02B | $432M | $439M |
| 2017 | $4.27B | $1.34B | $2.93B | $384M | — |
| 2016 | $3.85B | $1.27B | $2.58B | $456M | — |
| 2015 | $3.71B | $1.22B | $2.49B | $458M | — |
| 2014 | $3.34B | $1.16B | $2.18B | $413M | — |
| 2013 | $3.39B | $1.20B | $2.19B | $332M | $436M |
| 2012 | $3.44B | $1.43B | $2.02B | $463M | $733M |
| 2011 | $3.10B | $1.35B | $1.74B | $574M | $732M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $532M | $158M | $375M |
| 2024 | $455M | $166M | $290M |
| 2023 | $375M | $157M | $218M |
| 2022 | $194M | $113M | $82M |
| 2021 | $669M | $134M | $536M |
| 2020 | $585M | $109M | $476M |
| 2019 | $458M | $99M | $359M |
| 2018 | $285M | $130M | $156M |
| 2017 | $104M | $111M | -$7M |
| 2016 | $216M | $141M | $75M |
| 2015 | $186M | $112M | $74M |
| 2014 | $273M | $121M | $152M |
| 2013 | $169M | $107M | $62M |
| 2012 | $266M | $143M | $124M |
| 2011 | $263M | $103M | $160M |

Source: [CompaniesByCap](https://companiesbycap.com/company/BIO)